Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Jan Bewersdorf

Jan Bewersdorf

MD
Yale Cancer Center

Academic History

Jan Philipp Bewersdorf, MD, is an Assistant Professor of Medicine (Hematology) at Yale University. Dr Bewersdorf earned his medical degree in Germany, and completed his Internal Medicine training at Yale (New Haven Hospital). After his residency, Dr Bewersdorf pursued his fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center, New York, NY, before joining the faculty at Yale in July 2024.

Speaking on the pathophysiology of AML and MDS

Dr Bewersdorf is an up-and-coming young researcher, focusing on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He seeks to improve understanding of the underlying pathophysiology of these diseases, particularly the role of the immune system. Dr Bewersdorf also undertakes research into health economics and clinical epidemiology in order to improve patient care.

Phase Ib trial of entinostat in combination with pembrolizumab in R/R MDS or AML 2:10
Phase Ib trial of entinostat in combination with pembrolizumab in R/R MDS or AML
Jan Bewersdorf • 11 Dec 2022
Cost-effectiveness of azacitidine and ivosidenib in elderly patients with newly diagnosed IDH1m AML 2:54
Cost-effectiveness of azacitidine and ivosidenib in elderly patients with newly diagnosed IDH1m AML
Jan Bewersdorf • 11 Dec 2022
FUSION-AML-001: molecular changes associated with azacitidine & durvalumab in TP53m AML and HR-MDS 1:54
FUSION-AML-001: molecular changes associated with azacitidine & durvalumab in TP53m AML and HR-MDS
Jan Bewersdorf • 11 Dec 2022
Phase I study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis 2:10
Phase I study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
Jan Bewersdorf • 11 Dec 2022
Updates on maintenance therapies in AML 5:34
Updates on maintenance therapies in AML
Jan Bewersdorf • 14 Dec 2021
An analysis of TP53 mutation in AML and HR-MDS 5:16
An analysis of TP53 mutation in AML and HR-MDS
Jan Bewersdorf • 14 Dec 2021
Re-evaluating the use of IWG 2006 response criteria in MDS 4:31
Re-evaluating the use of IWG 2006 response criteria in MDS
Jan Bewersdorf • 14 Dec 2021
Analyzing the cost-effectiveness of CPX-351 in patients with AML 2:01
Analyzing the cost-effectiveness of CPX-351 in patients with AML
Jan Bewersdorf • 14 Dec 2021
Systematic review comparing allogeneic transplant patients with non-transplant patients in MF 2:30
Systematic review comparing allogeneic transplant patients with non-transplant patients in MF
Jan Bewersdorf • 24 May 2021
The ongoing use of ruxolitinib in myelofibrosis 1:58
The ongoing use of ruxolitinib in myelofibrosis
Jan Bewersdorf • 24 May 2021
Venetoclax and magrolimab for treatment of AML and MDS 2:53
Venetoclax and magrolimab for treatment of AML and MDS
Jan Bewersdorf • 24 May 2021
COVID-19: the growth of telemedicine, oral agents and disruptions in clinical trial operations 3:20
COVID-19: the growth of telemedicine, oral agents and disruptions in clinical trial operations
Jan Bewersdorf • 24 May 2021
The content of VJHemOnc is intended for healthcare professionals